Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Leukemia

• Publication date

  2016-06-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2016.161PMID 27389058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin’s B lymphoma cells from apoptosis

  2016cited by this paper
• Galectin 3 as a guardian of the tumor microenvironment.

  2016cited by this paper
• Lymphoma Microenvironment and Immunotherapy.

  2016cited by this paper
• Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.

  2016cited by this paper
• Novel immunotherapies in lymphoid malignancies

  2016cited by this paper
• Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

  2015cited by this paper
• Immune checkpoint blockade in hematologic malignancies.

  2015cited by this paper
• Immune checkpoint inhibition in lymphoid disease

  2015cited by this paper
• Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

  2015cited by this paper
• Macrophages and therapeutic resistance in cancer.

  2015cited by this paper
• Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.

  2015cited by this paper
• CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.

  2015cited by this paper
• A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

  2015cited by this paper
• Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

  2015cited by this paper
• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Mechanisms of action of therapeutic antibodies for cancer.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Blinatumomab for the treatment of B-cell lymphoma

  2015cited by this paper
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

  2015cited by this paper
• Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia

  2015cited by this paper
• A Novel Risk Locus at 6p21.3 for Epstein–Barr Virus-Positive Hodgkin Lymphoma

  2015cited by this paper
• PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro

  2015cited by this paper
• A genome-wide association study of marginal zone lymphoma shows association to the HLA region

  2015cited by this paper
• Genomic alterations underlying immune privilege in malignant lymphomas

  2015cited by this paper
• CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.

  2015cited by this paper
• Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP)

  2015cited by this paper
• The impact of HLA class I and EBV latency‐II antigen‐specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma

  2015cited by this paper
• How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia

  2015cited by this paper
• Critical role of the NKG2D receptor for NK cell‐mediated control and immune escape of B‐cell lymphoma

  2015cited by this paper
• Lymphoma: Immune Evasion Strategies

  2015cited by this paper
• Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

  2015cited by this paper
• Modeling HLA associations with EBV‐positive and ‐negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis

  2015cited by this paper
• The tumour microenvironment in B cell lymphomas

  2014cited by this paper
• Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

  2014cited by this paper
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

  2014cited by this paper
• SnapShot: diffuse large B cell lymphoma.

  2014cited by this paper
• The CD47-SIRPα signalling system: its physiological roles and therapeutic application.

  2014cited by this paper
• FAS system deregulation in T-cell lymphoblastic lymphoma

  2014cited by this paper
• Genetics of follicular lymphoma transformation.

  2014cited by this paper
• PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).

  2014cited by this paper
• tTregs, pTregs, and iTregs: similarities and differences

  2014cited by this paper
• Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

  2014cited by this paper
• New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

  2014cited by this paper
• Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

  2014cited by this paper
• Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

  2014cited by this paper
• Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

  2014cited by this paper
• Targetable genetic features of primary testicular and primary central nervous system lymphomas.

  2014cited by this paper
• Could treatment with R‐HCVAD/R‐MA as compared to R‐ CHOP truly result in improved outcomes for patients with high‐risk diffuse large B cell lymphoma? – Response to Landsburg et al

  2014cited by this paper
• Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities

  2014cited by this paper
• Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.

  2014cited by this paper
• The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Galectins in hematological malignancies

  2013cited by this paper
• Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

  2013cited by this paper
• Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma.

  2013cited by this paper
• The role of B7 family molecules in hematologic malignancy.

  2013cited by this paper
• Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

  2013cited by this paper
• Biochemical large-scale identification of MHC class I ligands.

  2013cited by this paper
• Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

  2012cited by this paper
• Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.

  2012cited by this paper
• Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma.

  2012cited by this paper
• The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia

  2012cited by this paper
• Context-specific roles for paracrine IL-6 in lymphomagenesis.

  2012cited by this paper
• Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

  2012cited by this paper
• Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications

  2012cited by this paper
• Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

  2012cited by this paper
• Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

  2011cited by this paper
• Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Immunopathogenesis of lymphoma: Focus on CCR4

  2011cited by this paper
• Making sense of regulatory T cell suppressive function.

  2011cited by this paper
• GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma

  2011cited by this paper
• MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

  2011cited by this paper
• Cancer-Immune Equilibrium: Questions Unanswered

  2011cited by this paper
• Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

  2011cited by this paper
• Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.

  2010cited by this paper
• Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes.

  2010cited by this paper
• Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

  2010cited by this paper
• Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

  2010cited by this paper
• Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

  2010cited by this paper
• Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.

  2010cited by this paper
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

  2010cited by this paper
• Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

  2009cited by this paper
• Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

  2009cited by this paper
• Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

  2009cited by this paper
• Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.

  2009cited by this paper
• Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity

  2009cited by this paper
• CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

  2009cited by this paper
• Identification of a chemokine receptor profile characteristic for mediastinal large B‐cell lymphoma

  2009cited by this paper
• Immune‐mediated dormancy: an equilibrium with cancer

  2008cited by this paper
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

  2008cited by this paper
• Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory.

  2008cited by this paper
• Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

  2008cited by this paper
• Stromal gene signatures in large-B-cell lymphomas.

  2008cited by this paper
• Regulation of MHC class I assembly and peptide binding.

  2008cited by this paper

• Evaluation of the association between serum danger molecules at diagnosis and survival outcomes in patients with diffuse large B cell lymphoma

  2025cites this paper
• In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?

  2025cites this paper
• Immune checkpoint inhibitors for multiple myeloma immunotherapy

  2023cites this paper
• The value of serum IL-4 to predict the survival of MDS patients

  2023cites this paper
• Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

  2022cites this paper
• Scaffold-mediated switching of lymphoma metabolism in culture

  2022cites this paper
• In Vivo and Ex Vivo Patient‐Derived Tumor Xenograft Models of Lymphoma for Drug Discovery

  2021cites this paper
• Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.

  2021cites this paper
• Chapter 9: Selenium and immunity

  2021cites this paper
• An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach

  2021cites this paper
• PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

  2021cites this paper
• Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study

  2021cites this paper
• Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises

  2021cites this paper
• The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

  2021cites this paper
• Chapter 16: Vitagenes in gut health and immunity

  2020cites this paper
• New Insights into Diffuse Large B-Cell Lymphoma Pathobiology

  2020cites this paper
• Characteristics of immunological synapse in mature B‐cell neoplasms

  2020cites this paper
• Identifying M1 Macrophage-Related Genes Through a Co-expression Network to Construct a Four-Gene Risk-Scoring Model for Predicting Thyroid Cancer Prognosis

  2020cites this paper
• New insights in Diffuse Large B Cell Lymphoma Pathobiology

  2020cites this paper
• Grade II/III glioma microenvironment mining and its prognostic merit.

  2019cites this paper
• Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy

  2019cites this paper
• Microfluidic assembly of hydrogel‐based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release

  2019cites this paper
• THE ROLE OF HISTOLOGY IN THE STUDY OF TUMOR CELL METABOLISM: THE TRAP1 PARADIGM

  2018cites this paper
• Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma

  2018cites this paper
• Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation

  2018cites this paper
• Chapter 7 Selenium and immunity

  2018cites this paper
• Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

  2018cites this paper
• Next-Generation Immunotherapy in Lymphoma: Checkpoint Blockade, Chimeric Antigen Receptor T Cells, and Beyond

  2018cites this paper
• Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?

  2017cites this paper
• Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?

  2017cites this paper
• Patient-Derived-Tumor-Xenograft: modeling cancer for basic and translational cancer research

  2017cites this paper
• Gingipain of Porphyromonas gingivalis manipulates M1 macrophage polarization through C5a pathway

  2017cites this paper
• Mutational landscape of Hodgkin lymphoma

  2016cites this paper